Thalidomide-amido-PEG2-NH2 hydrochloride is primarily utilized in the field of targeted drug delivery and proteolysis-targeting chimeras (PROTACs). Its structure allows it to act as a linker molecule, connecting a target protein ligand to an E3 ubiquitin ligase recruiter, such as thalidomide. This facilitates the degradation of specific proteins through the ubiquitin-proteasome system, making it valuable in the development of therapies for diseases like cancer, where selective protein degradation is crucial. Additionally, its PEG (polyethylene glycol) component enhances solubility and stability, improving the pharmacokinetic properties of the drug conjugate. This compound is particularly useful in research and development of novel therapeutic agents aimed at modulating protein levels in a controlled and targeted manner.